Navigation Links
DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
Date:4/16/2008

SAN MATEO, Calif., April 16 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that after completing its review of safety and efficacy data currently available, an independent Data Safety Monitoring Board (DSMB) has recommended that Anthera's Phase II clinical trial, known as the IMPACTS (Investigation of the Modulation of Phospholipase in Acute ChesT Syndrome) Study can continue under the current protocol, without change.

IMPACTS is a Phase II multi-center clinical trial evaluating the safety and effectiveness of intravenous A-001 (varespladib sodium) in preventing the development of acute chest syndrome in hospitalized sickle cell disease patients. Enrolled patients are at-risk for acute chest syndrome based on the combination of pain (vaso-occlusive crisis), fever, and elevated serum level of the enzyme (secretory phospholipase).

"We are pleased with the DSMB's response and look forward to continuing the A-001 trial under our original protocol," said Dr. James E. Pennington, M.D., Executive Vice President and Chief Medical Officer of Anthera Pharmaceuticals, Inc. "Treatment options are limited for this important patient population and we believe a drug that provides an opportunity for early intervention would help address a significant unmet medical need."

"Today's announcement marks another exciting milestone for Anthera," said Paul F. Truex, President and Chief Executive Officer of Anthera Pharmaceuticals, Inc. "Over the past few months, we've also made significant progress in our A-002 program for cardiovascular disease. In February, we completed our end of Phase II meeting with the FDA. In early April, we completed a pre-submission meeting with European Medicines Agency (EMEA). Presently, we are preparing to submit our registration protocols to FDA as part of the Special Protocol Assessment process."

About A-001

A-001 is a poten
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
2. Karmanos Cancer Institute Research Supports Role of Inflammation to Determine Lung Cancer Risk, Particularly in African-American Women
3. DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma
4. DSMB Again Supports Continuation of the Phase III Clinical Trial of Medidur(TM) FA for the Treatment of DME
5. Evanston Northwestern Healthcare Researchers Explain Effects of Large-Scale, Universal MRSA Surveillance Program That Supports Expanded Intervention
6. ACR Supports American Cancer Society Inclusion of CT Colonography (Virtual Colonoscopy) as Recommended Screening Tool for Colorectal Cancer in New Screening Guidelines
7. New Clinical Data Further Supports Chromium Picolinates Role in Enhancing Brain Activity in Older Adults
8. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
9. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
10. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
11. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014 Scott Steiger ... most of the world. As an engineer for the past 20 ... member of the military service. He,s been to six of the ... Photo - http://photos.prnewswire.com/prnh/20141126/161076 Photo - http://photos.prnewswire.com/prnh/20141126/161077 ... for travelers, he has a pretty good idea of what,s required. ...
(Date:11/26/2014)... -- Zynerba Pharmaceuticals , Inc., a specialty pharmaceutical ... cannabinoid treatments, today announced that the company will present ... The conference will be held December 2 to 3, ... York . Zynerba,s Chairman and CEO, Armando ... December 2. To listen to a webcast ...
(Date:11/26/2014)... , Nov. 26, 2014 The ... at a rate of 4%, with world market ... Kalorama Information. MRI and other types of medical ... and treatment of numerous medical conditions in children ... and techniques. Kalorama,s report, Medical Imaging Markets ...
Breaking Medicine Technology:Steiger Has Created the First Pill Case Specifically Designed For Travel 2Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2Kalorama: Steady Growth in the Medical MRI Market 2Kalorama: Steady Growth in the Medical MRI Market 3
... , , SEATTLE, Dec. 9 Omeros Corporation today ... to serve on the Company,s Board. Mr. Spiegelman has also been ... are very pleased to welcome Dan to our Board and look ... CEO of Omeros. "Dan brings a substantial depth and breadth of ...
... , WALTHAM, Mass., Dec. 9 Decision ... focusing on pharmaceutical and healthcare issues, finds that compared to ... are being used more often to treat newly diagnosed patients ... second-line patients received a TNF-alpha inhibitor versus one year ago ...
Cached Medicine Technology:Daniel K. Spiegelman Elected to Board of Directors of Omeros 2TNF-Alpha Inhibitors Are Being Used More Often To Treat Newly Diagnosed Patients With Crohn's Disease 2TNF-Alpha Inhibitors Are Being Used More Often To Treat Newly Diagnosed Patients With Crohn's Disease 3
(Date:11/28/2014)... Recently, BellasDress , a renowned dress manufacturer in the ... of cocktail dresses. In addition, these fresh dresses are available ... shipping on orders over $179. The aim of the special ... providing many styles of dresses, which come in various colors; ... more. All of them are on sale at affordable prices. ...
(Date:11/28/2014)... November 29, 2014 Recently, SWAccessControl.com, a ... systems. At the moment, all these high end products ... off. The special offer will last from today to ... “We are happy to launch the promotion. We are ... worldwide distributors with the latest information about our hottest ...
(Date:11/28/2014)... Recently, PrettyTailor.com has developed and created its new collection ... world in celebration of the coming holiday season. To ... special offer on all these outfits. Click here ... the garment industry, PrettyTailor.com brings together art and technology ... The business carries quite a few in eye-catching patterns ...
(Date:11/28/2014)... The month of December has the highest ... occurring in Florida every year in December , attorney Sean ... insurance policies. , "Optional auto insurance coverage is something you ... cheap I know, actually Florida is among the states, where ... but what I see is that the insurance required by ...
(Date:11/28/2014)... News) -- People with diabetes face a number of challenges ... healthy, an expert says. "With the holidays coming, take ... events, the family you,ll be visiting and all of the ... Educators, said in an association news release. "By planning ahead. ... One idea is to make a healthy eating contract with ...
Breaking Medicine News(10 mins):Health News:BellasDress Offers A Big Surprise By Updating Its Cheap and Charming Cocktail Dresses 2Health News:New Access Control Systems Now Offered At Low Prices By Smartware Manufacturer SWAccessControl.com 2Health News:2015 Wedding Dresses from PrettyTailor.com Available Now 2Health News:Car Accident Attorney Sean M. Cleary on Auto Insurance Policies Essential for Florida Drivers 2Health News:Holiday Eating Tips for People With Diabetes 2
... sedimentation rate (ESR) increases during pregnancy. Also, both ... ,The erythrocyte sedimentation rate is one of ... is helpful in detecting the presence of inflammation ... by anaemia, which may be present in inflammatory ...
... to be in critical condition in a hospital here where ... government said. // ,Narayanan, who turned 85 ... and Referral Hospital two days later and has been on ... his condition. He continues to be critical, the aide said. ...
... are now produced which has been found to have ... Immunotherapy vaccines. //Antibodies against the allergen is given as ... allergen or infection these antibodies which are already present ... ,Conventional antibody injections against allergy diseases such ...
... the November issue of the Journal of the National Cancer ... after treatment, and patients treated with the higher chemotherapy dose ... ,Germ-cell testicular cancer is the most common cancer among 20-40 ... an age at which they are starting a family, and ...
... is a FDA approved long-term treatment regime for patients ... therapy is now being offered to patients at NewYork-Presbyterian ... now the first treatment specifically approved for TRD in ... therapy has been unsuccessful atleast in four or more ...
... cancer does not mean that you can cool your heels, ... experts have warned people. // ,These warnings were ... by eminent doctors who took part in a panel discussion ... In a keynote address delivered on the occasion, Prof D ...
Cached Medicine News:Health News:Oral Edible vaccine for Allergy Vaccines 2Health News:Decline in Paternity Rates Following Treatment for Testicular Cancer 2Health News:FDA Approved Nerve-Stimulation Therapy Now Available In New York 2
... Infinity Triglycerides powder reagent once reconstituted ... of single liquid stability to help ... and provide quick result turnaround time. ... Triglycerides powder reagent provides a long ...
... single liquid stable reagent offers the ... liquid stability to help maximize laboratory ... quick result turnaround time. The patented ... provides a long shelf life that ...
... Infinity Creatinine single liquid stable reagent ... of single liquid stability to help ... and provide quick result turnaround time. ... Creatinine reagent provides a long shelf ...
... Amylase powder reagent once reconstituted offers ... single liquid stability to help maximize ... provide quick result turnaround time. The ... powder reagent provides a long shelf ...
Medicine Products: